NNorwest is a venture and growth equity firm that partners with world‑class entrepreneurs to support their growth and professional development. It manages more than $15.5 billion in capital and has invested in over 700 early‑ to late‑stage companies, with more than 250 currently active. Its focus spans consumer, enterprise, and healthcare, and it provides businesses with resources, expertise, guidance, and connections to help them achieve their vision. Norwest differentiates itself by working side‑by‑side with founders, offering hands‑on support, and leveraging its global network of offices in Menlo Park, San Francisco, and subsidiaries in India and Israel. The company's goal is to help entrepreneurs scale their businesses and reach their long‑term objectives.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
N/A
Total Funding
$30.6B
Headquarters
Palo Alto, CA
Founded
1961
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$30.6B
Above
Industry Average
Funded Over
0 Rounds
San Francisco-based Above Security has joined the Microsoft for Startups Pegasus Program, an invitation-only scheme that connects selected business-to-business technology startups with Microsoft's global customer network. The move follows a $50 million funding round led by Ballistic Ventures, Merlin Ventures, and Norwest, with a strategic investment from CrowdStrike's Falcon Fund. Above Security's AI-powered platform helps organisations investigate insider data risks using their existing Microsoft security tools, including Purview, Defender for Endpoint, and Entra ID. Its AI agents build incident timelines and can propose data loss prevention policies for Purview. The platform is available on Microsoft's Azure Marketplace. Above Security will demonstrate the Purview integration at Microsoft Ignite in San Francisco on November 17–18.
‘Electronics design hasn’t changed in 40 years,’ says Circuit Mind’s CEO, as the London startup raises $25m for AI circuit board design.
We are thrilled to announce eGateway Capital’s investment in Third Wave Automation’s Series C. Third Wave Automation (“TWA”) is redefining warehouse and supply chain operations with its AI-powered shared autonomy system, transforming traditional forklifts into intelligent, self-operating machines. With labor shortages and rising costs pushing the logistics industry toward automation, TWA’s human-in-the-loop AI model enables safer, more efficient, and scalable material handling. TWA is solving one of the most pressing bottlenecks in logistics with a scalable, capital-efficient model that delivers immediate ROI to operators. Their blend of autonomy and human oversight allows for real-world adoption today — not in five years. With a massive addressable market and growing demand for automation, we believe TWA is well-positioned to lead the future of AI-powered material handling. The future of supply chain automation is here, and we’re thrilled to partner with Arshan Poursohi, Julian (Mac) Mason, and the entire Third Wave team as they lead the way in AI-driven logistics. #AI #Automation #SupplyChainAutomation #SupplyChainInnovation #VentureCapital
Norwest has made a noteworthy investment of over Rs 300 crore in SILA Properties, valuing the company at Rs 1,000 crore. This strategic funding marks a pivotal growth equity move within India's real estate arena. SILA intends to leverage this capital for land acquisitions and the development of luxury residential properties in Mumbai and Alibaug, with aspirations to attract more institutional investment through tailored platforms.
Matchpoint Therapeutics has closed a $150 million Series B financing round to advance its pipeline of oral small molecules for autoimmune and inflammatory diseases. The round was co-led by Nextech Invest and Norwest, with participation from new investors Invus, BB Biotech, T1D Fund, and BOLD Longevity Growth, alongside existing investors including Access Biotechnology, Atlas Venture, and Sanofi Ventures. The Watertown, Massachusetts-based biotech will use the proceeds to progress its lead asset, MPT-062, an oral first-in-class T cell modulator, towards clinical proof-of-concept. Clinical development is expected to begin in 2027. The company will also continue advancing its broader pipeline, including a programme funded through a July 2025 agreement with Novartis. Kanishka Pothula and Brian Matesic will join Matchpoint's board of directors.
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
N/A
Total Funding
$30.6B
Headquarters
Palo Alto, CA
Founded
1961
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs